downloadCannabics Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and production of proprietary technologies for treating a wide range of indications through medical cannabis.

The flagship product of Cannabics is the Cannabics SR capsule, a sustained release capsule that provides palliative care to patients suffering from certain types of cancer. The Cannabics SR capsule uses a patented formulation and contains cannabinoids pure concentrate. Cannabinoids are extracted from various strains of the cannabis plant selected and bred by the company. Each capsule provides 10 to 12 hours of therapeutic effects, which allows for once-per-day dosage.

Cannabics Pharmaceuticals, Inc. also supplies other products in the company line, including the condensed Cannabis VP pill for standard vaporizers, and the capsule Cannabics IN for dry powder inhalers. As of 2013, the products of the company have circulated through five hospitals in Israel, where medical marijuana use is permitted for cancer patients and for treatment for pain-related illnesses.

Cannabics Pharmaceuticals, Inc., through its research and development extension in Israel, is developing a pipeline of advanced cannabinoid-based therapies. With the company’s collaboration with major medical centers in the U.S., Israel, and Europe, Cannabics is now launching clinical studies investigating the beneficial effects of their products in a wide range of medical indications.

Cannabics Pharmaceuticals, Inc. is a subsidiary of Cannabics, Inc., and was founded in 2012 by research experts in the fields of molecular biology, cancer research, and pharmacology.  The company, which is based in Bethseda, Maryland, was known as Thrust Energy Corp until 2011, and as American Mining Corporation until June in 2014.

Cannabics Pharmaceuticals, Inc. is traded in the OTC Markets under the stock symbol CNBX. The company’s key executives are Dr. Zohar Koren, CEO and Co-founder; Dr. Eyal Ballan, CTO and Co-founder; and Itamar Borochov, Marketing VP.


Yahoo! Finance: CNBX News

Latest Financial News for CNBX

Cannabics Pharmaceuticals Appoints a Second Independent Board Member

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has appointed Dr. Gil Feiler to its Board of Directors as an Independent Director. Dr. Feiler, 62, who until now served as a Permanent Observer on the company's Board, is a world-renowned economist and currently serves also as the company's Head of Advisory Board. Dr. Feiler holds a PhD in Middle East Economics from Tel Aviv University, and is a g

Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has appointed Dr. Inbar Maymon-Pomeranchik to its Board of Directors as an Independent Director. Dr. Maymon-Pomeranchik, 43, is trained as a molecular and genetic researcher holding a PhD from the Hebrew University, and brings nearly 20 years of executive level experience in biotech sciences, with particular expertise in the global medical cannabi

Cannabics Pharmaceuticals' Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, released today the interim results of its second in-vivo POC study evaluating the efficacy of company's proprietary drug candidate RCC-33 for the treatment of colorectal cancer on mice. The study objective was to evaluate the potential efficacy of the RCC-33 drug candidate as a systemic treatment for colorectal cancer when administered orally. Interim study results confi

Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the expansion of its research program with new drug development projects targeting Prostate Cancer, Neurodegenerative & Mental Health diseases. The announcement of the new research projects follows promising initial preclinical results obtained in the company's in-house drug discovery facility in Rehovot, Israel. Study results indicate the potential effic

Cannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the launching of a new research program for the development of a Breast Cancer antitumor targeting medicine.